Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
7493
Tickers With News
507
Showing Now
80
Top Ticker
TSLA
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
Camden Property Trust (CPT) rated Hold: Sunbelt REIT with ~95% occupancy, strong balance sheet, and dividend coverage. See here for more details.
Simon Property Group, Inc. (NYSE:SPG) is one of the 12 Most Profitable Stocks to Invest In. On May 19, 2026, Scotiabank raised the firm’s price target on Simon Property Group, Inc. (NYSE:SPG) to $206 from $192 and maintained a Sector Perform rating on the shares. Scotiabank said it was updating price targets for U.S. Retail […]
Johnson & Johnson (NYSE:JNJ) is one of the cheap robotics stocks to buy right now. On May 12, Johnson & Johnson (NYSE:JNJ) confirmed the global launch of the Shockwave C2 Aero Coronary IVL Catheter for the treatment of calcified coronary artery disease, as it seeks to redefine the standards of coronary IVL with efficient, predictable […]
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Shares of the electric-vehicle maker were up 1.4% at $396.65 in premarket trading, while futures were up 0.4% and futures were down 0.1%. Investors are waiting to see if some investors will sell Tesla stock to buy SpaceX shares. Technical factors like that can create short-term price distortions.
Tesla retail sales in China grew 22% year-over-year in May, ending a two-month decline. Tesla stock rose modestly early Monday after diving last week.
Tesla, Inc. is a Strong Buy on EV growth, FSD and robotaxi catalysts, and undervalued owner earnings. Click for this TSLA stock update.
Tesla shares have historically been an unstoppable force, but it's now time for investors to assess the company's valuation.
SpaceX just filed an amendment to its IPO documentation, and one sentence suggests a major deal could be on the horizon.
The brutal AI selloff that rocked the market on Friday may end up being short-lived, judging by how chip makers are trading Monday.
Eisman on Monday expressed skepticism about SpaceX potentially merging with EV Giant Tesla Inc (TSLA), highlighting the latter company’s many challenges.
Dow Jones Futures: President Trump and Iran's comments sparked a tech rebound Monday. Micron, Nvidia and Sandisk were big winners.
Weyerhaeuser Company (WY) Nareit REITweek: 2026 Investor Conference June 2, 2026 8:45 AM EDTCompany ParticipantsDevin Stockfish - President, CEO &...
Weyerhaeuser Co (NYSE:WY) is one of the best land and timber stocks to buy now. The Street expects Weyerhaeuser stock to jump more than 26% from its current level. Weyerhaeuser Co (NYSE:WY) reported its Q1 2026 results on April 30. The company delivered $1.73 billion in net sales and $77 million in adjusted net earnings, […]
Recent performance snapshot for Weyerhaeuser (WY) Weyerhaeuser (WY) has drawn fresh attention after recent trading left the stock around $24.48, with returns mixed, up about 4.0% over the past month but only slightly positive over the past three months. See our latest analysis for Weyerhaeuser. Zooming out, the share price has had a modest 2.9% year to date gain, while the 1 year total shareholder return is down 5.2%, pointing to muted momentum despite recent short term stability around...
Mettler-Toledo International recently reported a strong first-quarter 2026 performance, with 3% local currency revenue growth, an earnings beat and raised full-year adjusted EPS guidance, even as management flagged geopolitical and demand uncertainty, particularly in Europe. Fresh analyst coverage, including Wolfe Research’s new Peerperform rating alongside a cluster of buy recommendations, highlights confidence in the company’s innovation pipeline and cash-generative model, especially in...
Welltower (WELL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wondering if Welltower at US$205.33 is offering fair value or a stretched price? This article walks through the key valuation angles so you can judge for yourself. The stock is up 9.8% year to date and 35.1% over the past year, although it has recently fallen 5.0% over the last week and 3.2% over the past month. Recent headlines have focused on Welltower's position as a major health care real estate owner, with investors watching how sector sentiment and capital flows affect large REITs...
Wells Fargo analyst John Kilichowski maintains Welltower (NYSE:WELL) with a Overweight and raises the price target from $228 to $237.
Welltower Inc. (NYSE: WELL) ("Welltower" or the "Company") today announced that it expects to raise its quarterly common stock dividend to $0.85 per share, beginning with the second quarter of 2026. The declaration and payment of any future dividend remains subject to further review and approval by the Board.
Welltower stock performance snapshot Welltower (WELL) has drawn investor attention after a period in which the stock is up about 29.1% over the past year, despite declines of 3.9% in the past day and 9% over the past month. See our latest analysis for Welltower. Recent share price weakness, with the stock down 9% over the past month, sits against a much stronger backdrop, as Welltower’s 1 year total shareholder return of 29.1% points to longer term momentum. If you are comparing Welltower...
WELL plans a 15% quarterly dividend hike to 85 cents per share, signaling strong cash flow, low payout ratios and confidence in future growth.
The REIT is thriving as a play on retirement housing. It may need flawless execution to keep moving up.
While Welltower has underperformed the S&P 500 recently, analysts remain highly optimistic about the stock’s prospects.
Welltower Inc. (NYSE:WELL) is one of the 10 Best American Stocks to Buy and Hold for the Next Decade. On May 26, 2026, BofA raised the firm’s price target on Welltower Inc. (NYSE:WELL) to $277 from $260 and maintained a Buy rating on the shares. BofA updated its models following Q1 earnings from healthcare REITs. […]
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
VEEV and IQV are benefiting from life sciences digitization trends, but differences in growth, AI adoption and valuation set them apart.
Since November 2025, Quest has been in a holding pattern, posting a small return of 2.6% while floating around $194.06. The stock also fell short of the S&P 500’s 9.8% gain during that period.
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Quest Diagnostics is in focus today as the latest update shows no changes to the current price targets set by covering analysts. Even without fresh commentary driving the story, the lack of adjustment itself can be useful context as you think about how the stock fits into your watchlist or portfolio. Read on to see how to monitor future shifts in the analyst narrative so you can stay on top of what changes and what stays the same. Wall Street's queuing for one rocket. While SpaceX counts down...
Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the 12 Most Profitable Stocks to Invest In. On May 21, 2026, Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Health Canada accepted for review a New Drug Submission for suzetrigine for the treatment of moderate-to-severe acute pain in adults. Vertex said suzetrigine is a selective NaV1.8 pain signal inhibitor and represents […]
Vertex Pharmaceuticals Incorporated (VRTX) Bernstein 42nd Annual Strategic Decisions Conference May 29, 2026 9:00 AM EDTCompany ParticipantsReshma...
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.
Vertex Pharmaceuticals recently reported that the FDA accepted its Biologics License Application for povetacicept in adults with immunoglobulin A nephropathy, with a PDUFA action date set for November 30, 2026, supported by Phase 3 data showing clinically meaningful reductions in proteinuria. This milestone marks a potential first commercial product in Vertex’s nephrology franchise, signaling progress in diversifying beyond its cystic fibrosis core. Next, we’ll explore how the FDA’s...
If you are wondering whether Vertex Pharmaceuticals at around US$438 per share is priced attractively or already reflects its strengths, you are not alone. The stock has inched up 0.9% over the past week and 3.4% over the past month, while year to date it is down 3.0% and the 1 year return is also down 1.6%. This is set against a 31.1% gain over 3 years and a 109.6% gain over 5 years. These moves sit against a backdrop of ongoing interest in Vertex's pipeline and its position in treatments...
Stock performance snapshot Vertex Pharmaceuticals (VRTX) is drawing investor attention after recent trading left the stock around US$446.83, with returns mixed across different periods and a longer term track record that stands in contrast to more recent moves. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been choppy, with a 1-day share price return of 1.15% and a 30-day share price return of 4.49%, while the 1-year total shareholder return has slipped 0.81% and the...
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific Corporation (NYSE:BSX) is among the 10 Most Oversold S&P 500 Stocks So Far in 2026. On May 29, Wolfe Research downgraded the stock from Outperform to Peer Perform. This marks the end of the firm’s bullish outlook on the stock for four years, with the adjustment coming after the company said sales growth […]
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best and worst performers in the medical devices & supplies - diversified industry.
Boston Scientific has considerably underperformed its sector peers recently, yet analysts remain highly optimistic about the stock’s prospects.
Boston Scientific enters this update cycle with no changes to its current price target, leaving expectations exactly where analysts previously set them. With no new analyst commentary on the stock, the story is less about fresh opinions and more about how existing views are holding steady for now. Ahead, you will see how to track this kind of quiet reset and what it can signal as the narrative around Boston Scientific continues to evolve. Stay updated as the Fair Value for Boston Scientific...
Boston Scientific (BSX) concluded the recent trading session at $48.85, signifying a +2.43% move from its prior day's close.
In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of expectations, but cut near-term and full-year guidance amid intensifying cardiac market competition and slowing growth in its Watchman stroke-prevention device. This combination of strong recent performance and a more cautious outlook, reinforced by downgrades from firms like Wolfe Research, has sharpened investor focus on how resilient Boston Scientific’s growth drivers...
Boston Scientific Corporation (NYSE:BSX) is one of top cheap stocks with Strong Buy ratings on Wall Street. Boston Scientific Corporation (NYSE:BSX) received a rating update from Canaccord on June 1. The firm lowered the price target on the stock to $70 from $71, reiterating a Buy rating on the shares. Canaccord stated that it updated […]
Boston Scientific Corporation (NYSE:BSX) is one of the oversold stocks to buy right now. On May 18, Boston Scientific entered into an accelerated share repurchase/ASR agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock, part of a previously authorized $5 billion program. The company will immediately receive approximately 30.4 million […]
Boston Scientific was down about 0.7% at close, while Lowe's Companies ended the session 3% lower, and Conagra Brands fell by about 1.3%.
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
UHS will establish a new nonprofit to absorb financial responsibility of GW University’s debt-ridden physician practice group. Executives told Healthcare Dive the deal should help stabilize those clinical operations in the D.C. region.
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Talkspace, Inc. (“Talkspace”) (Nasdaq: TALK) today announced that at the special meeting of Talkspace stockholders held on May 29, 2026, the Talkspace stockholders voted to approve the acquisition of Talkspace by Universal Health Services, Inc. (“UHS”) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of March 9, 2026 (the “Merger Agreement”), by and among Talkspace, UHS and UHS Merger Subsidiary, Inc., an indirect wholl
Is UHS a good stock to buy? We came across a bullish thesis on Universal Health Services, Inc. on r/ValueInvesting by Dynaheir-be. In this article, we will summarize the bulls’ thesis on UHS. Universal Health Services, Inc.’s share was trading at $150.12 as of May 28th. UHS’s trailing and forward P/E were 6.44 and 6.56 respectively according […]
LYB vs. AIQUY: Which Stock Is the Better Value Option?
Wells Fargo Upgrades LyondellBasell Industries N.V. (LYB)
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Stock performance snapshot and recent context LyondellBasell Industries (LYB) stock has pulled back about 11% over the past month, while still showing a gain of roughly 2% over the past 3 months and about 52% year to date. Over the past year the stock has returned around 29%. However, the 3 year and 5 year total returns show declines of about 11% and 15%. This provides important context for anyone reviewing the recent move. See our latest analysis for LyondellBasell Industries. Recent moves...
LyondellBasell Industries (NYSE:LYB) is one of the most undervalued stocks to buy and hold for 2 years. On May 1, LyondellBasell finalized the sale of select European olefins and polyolefins assets to AEQUITA, marking a significant milestone in the company’s ongoing European strategic assessment. This divestiture aligns with LyondellBasell’s broader strategy to refine its portfolio, […]
Zoetis (ZTS) is back in focus after a cluster of securities class action filings, all tied to weakening demand, rising competition, and safety concerns in its flagship Companion Animal portfolio. See our latest analysis for Zoetis. At a share price of $79.52, Zoetis has seen short term volatility with a 1 day share price return of 2.49% and 7 day share price return of 1.60%. However, momentum has been weak over longer periods, with the 30 day share price return down 29.34%, the 90 day share...
Zoetis Inc. (NYSE:ZTS) is one of the oversold stocks to buy right now. On May 28, Zoetis received approval from the UK’s Veterinary Medicines Directorate for Lenivia (izenivetmab), a new long-acting monoclonal antibody therapy for alleviating osteoarthritis pain in dogs. Administered as a single injection, the treatment targets nerve growth factor to provide effective pain […]
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Zoetis Inc. (NYSE:ZTS) is among the most undervalued stocks to invest in. TheFly reported on May 27 that Argus downgraded ZTS from Buy to Hold following a sharp decline in the company’s share price, including a steep one-day drop of about […]
Zoetis Inc. (ZTS) 46th Annual William Blair Growth Stock Conference June 2, 2026 2:20 PM EDTCompany ParticipantsWetteny Joseph - Executive VP &...
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
https://www.apple.com/apple-events/event-stream/
Apple debuted its iOS 27 at its annual developer conference on Monday.
Siri is becoming a more capable AI assistant, and a key issue that Wall Street has been waiting to see. Apple showed off an updated Siri that can answer specific questions better than before while also taking actions on behalf of the user. In a demo at WWDC, an executive asked Siri to take certain actions, like finding specific photos and adding them to an album, setting calendar reminders, and more.
Apple stock slipped into negative territory on Monday as Wall Street seemed underwhelmed by the company's artificial intelligence updates. Shares were down 1% to $304.42 about an hour into the WWDC keynote.
CUPERTINO, Calif., June 08, 2026--Apple® today introduced the next generation of Apple Intelligence™, powered by a bold new architecture that integrates the latest Apple Foundation Models deep into Apple’s platforms and is uniquely designed to protect users’ privacy. This makes the apps and experiences users rely on every day across iPhone®, iPad®, Mac®, Apple Watch®, AirPods®, and Apple Vision Pro® more personal and helpful than ever. Apps become smarter and more useful with powerful editing ca
CUPERTINO, Calif., June 08, 2026--Apple® today previewed a new suite of powerful, intuitive, and easy-to-use features designed to allow parents to more easily manage the content their children can see, who they can communicate with, and when they have access to apps. With software updates this fall, parents will be able to access new child safety features, including a simpler setup experience with a recommended set of essential apps, Ask to Browse, Time Allowances, and a redesigned Screen Time.
CUPERTINO, Calif., June 08, 2026--Today, during the Worldwide Developers Conference, Apple® previewed its upcoming software releases that will deliver the next generation of Apple Intelligence™ and introduce Siri® AI, an entirely new version of Siri that is profoundly more intelligent, knowledgeable, and capable. The releases also bring powerful and intuitive new features to help parents create safe digital experiences for kids, as well as improvements that further elevate the software design an
CUPERTINO, Calif., June 08, 2026--Apple® today introduced Siri® AI, an entirely new version of Siri, powered by Apple Intelligence™. A profoundly more capable and conversational assistant with personal context understanding, broad world knowledge, and onscreen awareness, Siri AI can help users find what they need in the moment, from answering questions from the web on virtually any topic, to surfacing relevant information from a user’s personal messages, emails, photos, and more. Siri AI also in
Wedbush analyst Dan Ives says Apple is finally entering the AI game in a meaningful way, creating a new path for services growth that could drive further upside for the stock.
Apple unveiled the long-delayed, AI-powered version of its Siri assistant at its WWDC event on Monday.
Apple Inc (NASDAQ:AAPL, XETRA:APC) kicked off its annual Worldwide Developers Conference with what Wedbush analysts are calling the beginning of a foundational AI consumer platform shift, as the iPhone maker delivered on promises made two years ago with a more robust artificial intelligence...
Apple unveiled an artificial intelligence overhaul for the iPhone on Monday, turning to Google for help two years after the company stumbled on a first attempt.In the first quarter of this year, Apple iPhone sales grew by double digits in just about every country where it does business. arp/bgs
Apple (AAPL) kicked off its 2026 Worldwide Developers Conference (WWDC) on Monday by showcasing its new AI-powered Siri, dubbed Siri AI. Geoffrey Cain — the author of "Steve Jobs in Exile" — comes on Market Domination to comment on Apple's new position on AI and whether that could put pressure to keep up with its Big Tech peers. This is Apple CEO Tim Cook's final WWDC keynote as chief executive before he steps down in September and takes on a new role as executive chairman.
Iron Mountain (IRM) scores 9/10 on technical strength and setup quality, offering a clean breakout entry near $128.86 with defined risk.
Why Iron Mountain Is Drawing Fresh Attention Iron Mountain (IRM) is attracting fresh attention after a strong past 3 months, with the stock showing a 23.8% total return and a 56.5% gain year to date. See our latest analysis for Iron Mountain. At a share price of $130.25, Iron Mountain’s recent 1-day and 7-day share price returns of 1.8% and 2.7% sit against a 90-day share price return of 23.8% and a 3-year total shareholder return of 158.5%. This indicates momentum that has built over time...
If you are wondering whether Danaher stock is starting to look more interesting at its current price, this breakdown will help you judge if the valuation really stacks up. Over the short term, the stock has risen 4.6% over the past week and 2.7% over the past month. Year to date, the share price is down 21.9% and the 1-year return is down 4.3% from a last close of US$179.87. Recent coverage has focused on how investors are reassessing large healthcare and life sciences companies as interest...
2026-06-01. The following slide deck was published by Moderna, Inc.
Moderna (NASDAQ:MRNA) announced on Monday a new collaboration with an international health organization aimed at accelerating the development of a vaccine targeting Bundibugyo ebolavirus (BDBV), the strain responsible for the ongoing Ebola outbreak in eastern Democratic Republic of Congo. The partnership comes as global health agencies intensify efforts to identify effective treatments and preventive measures for the outbreak, which has resulted in more than 900 suspected infections and over 220
